Patent ID: 8722722

Claim:
A crystalline form of Raltegravir potassium that is: a) crystalline Form V of Raltegravir potassium, characterized by: an X-ray powder diffraction pattern having peaks at 8.0, 11.9, 18.2 and 26.6 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 2 ; a solid-state 13 C NMR spectrum with signals at 121.9, 144.0, 149.3 and 170.3±0.2 ppm; a solid-state 13 C NMR spectrum having chemical shifts differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 100 to 180 ppm of 111.9, 134.0, 139.3 and 160.3±0.1 ppm; a solid-state 13 C NMR spectrum substantially as depicted in FIG. 31 ; or combinations thereof; or b) crystalline Form IV of Raltegravir potassium, characterized by: an X-ray powder diffraction pattern having peaks at 6.5, 7.5, 8.1, 18.4 and 23.2 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 1 ; or combinations thereof.